BioLoomics, a Boulder, CO-based biotech company, raised $8.7M in Seed funding.
The round was led by Innovation Endeavors, with participation from Horizons Ventures, TechU Ventures, Boom Capital Ventures, Hummingbird Nomads Fund, Cooley GC&H, BoxOne Ventures and Viswa Colluru (Founder of Enveda).
The company intends to use the funds to advance its proprietary platform technology and antibody degrader programs and form strategic partnerships with large pharma companies.
Led by Dr. Douglas Chapnick, Founder and CEO, BioLoomics is a preclinical stage biotechnology company pioneering directed evolution of target degrading antibodies using human cells. Launched by a founding team with roots in the DARPA Rapid Threat Assessment (RTA) program, it combines expertise in robotics, synthetic biology, and machine learning. Using a mixture of synthetic biology and computer vision guided cell picking, its technology can effectively navigate through antibody design space in search of designs that leverage new mechanisms for target degradation.